Pharma and BioTech Daily

EXPLORE

Society & Culture

Health & Fitness

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2e/6f/bd/2e6fbd0f-388e-86bf-3355-a306edd50f8d/mza_4523107895456280344.jpg/600x600bb.jpg

Pharma and BioTech Daily

Pharma and BioTech News

63 episodes

1 day ago

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufac...

Show more...

All content for Pharma and BioTech Daily is the property of Pharma and BioTech News and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufac...

Show more...

Episodes (20/63)

Pharma and BioTech Daily

Pharma and Biotech Daily: The Latest in Cell and Gene Therapy, M&A Activity, and Regulatory Updates

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufac...

1 day ago

1 minute

Pharma and BioTech Daily

The Essential Updates in Pharma and Biotech: Your Daily Dose of What Matters

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Former NIAID director Jeanne Marrazzo was fired after filing a whistleblower report, alleging retaliation. The FDA's new cell and gene therapy guidances have been well-received for streamlining therapies. In other news, CMS has finalized stronger protections for orphan drugs, and Amgen's Repatha has shown positive results in preventing heart disease. Lotte Biologics ...

2 days ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Top Stories from the Industry

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. President Trump has once again delayed the imposition of 100% tariffs on pharmaceuticals, with preparations now set to begin on October 1. Halozyme's acquisition of Elektrofi for $900 million has brought two major pharmaceutical partners together, while Takeda is exiting the cell therapy sector and laying off 137 employees. Roche's $3.5 billion takeover of 89bio wa...

5 days ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Navigating Industry Shifts and Emerging Trends

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...

6 days ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Metsera's Mid-Stage Success, AI in Drug Production, and GSK's CEO Resignation

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for sp...

1 week ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Genmab Acquires Merus, GSK CEO Steps Down, FDA Transparency Concerns, and More!

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next yea...

1 week ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Trump's Tariff Deadline, FDA Approvals, and Price-Lowering Efforts

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the U.S. are exempt from these tariffs. This move is part of the administration's efforts to lower drug prices and improve access to treatments for patients.In other news, Crin...

1 week ago

1 minute

Pharma and BioTech Daily

Promising Results for Atebimetinib in Pancreatic Cancer & Other Pharma Updates

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid...

1 week ago

Pharma and BioTech Daily

The Rise and Challenges of Chinese Biotech: A Global Powerhouse Facing Financial Hurdles

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Uniqure's gene therapy for Huntington's disease, AMT-130, has shown promising results in a 3-year study, slowing disease progression by 75%. If approved, it would be the first genetic treatment for Huntington's. Meanwhile, Acadia Pharmaceuticals has discontinued a Prader-Willi drug after a late-stage failure. Biogen received an unexpected FDA rejection for a high dose...

1 week ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: FDA Revives Drug for Autism, Tylenol Pregnancy Warning, and More!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has revived a long-dormant drug from GlaxoSmithKline as a potential treatment for autism. The agency also mentioned the potential link between the use of Tylenol and other acetaminophen products during pregnancy and neurological and developmental defects in children. In other news, Scholar Rock's spinal muscular atrophy drug faced manufacturing site issues, w...

2 weeks ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Pfizer's Comeback, FDA Approvals, and Industry Updates

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Pfizer has made a comeback in the obesity market with the acquisition of Metsera for $4.9 billion, rejuvenating its portfolio after facing challenges with three discontinued assets. Meanwhile, Stealth BioTherapeutics has received expedited FDA approval for the first-ever treatment for Barth syndrome, and Sanofi's decision on their oral multiple sclerosis drug has b...

2 weeks ago

Pharma and BioTech Daily

Pharma & Biotech Daily: ACIP Updates, Stock Crashes, Rebranding, Layoffs & More

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The Advisory Committee on Immunization Practices (ACIP) has changed its recommendations for the MMRV vaccine for children under four, advising that the measles, mumps, rubella (MMR) vaccine be administered separately from the chickenpox vaccine. The committee is also expected to make changes to the childhood schedule for hepatitis B and COVID-19 vaccines. Replimune's...

2 weeks ago

Pharma and BioTech Daily

Navigating Uncertainty: Updates from the Pharma and Biotech World

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has made a significant move in the pharmaceutical industry by acquiring 89bio for $3.5 billion, with a contingent value right of $6 per share. The acquisition includes pegozafermin, an analog in late-stage development for metabolic dysfunction-associated steatohepatitis. Meanwhile, former CDC director Susan Monarez spoke to the Senate about her firing, allegin...

2 weeks ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Navigating the Ever-Evolving Landscape

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of th...

2 weeks ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Novo's Breakthrough Drug, Sarepta's DMD Therapy, and Industry Trends

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Novo's amylin analog drug, cagrilintide, has shown a significant 11.8% weight loss in a phase III trial, with improved safety data to address past tolerability issues. The FDA is set to make a decision on the drug, with significant stakes for the company and the Barth Syndrome community. Additionally, Sarepta's DMD gene therapy is still being prescribed by doctors ...

3 weeks ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Novartis' $5.7 Billion Deal and Myasthenia Gravis Market Flourishing

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novartis and Monte Rosa have entered into their second molecular glue deal worth up to $5.7 billion, with Novartis putting $120 million upfront for more of the biotech's AI-discovered degraders. The myasthenia gravis market, once sparse, is now flourishing with new treatments approved and promising late-stage trial results from companies like Argenx and Regeneron. In ...

3 weeks ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Trump Considers Tariff Exemptions and More

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump is considering exempting certain "non-patented" pharmaceuticals from tariffs, although specific guidelines have not yet been released. The Intercept has withdrawn a liver drug from the US market, and Ocaliva, approved for primary biliary cholangitis in 2016, did not receive full approval last year. Merck is cutting 125 employees in the UK as it ends ...

3 weeks ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Stay Informed, Stay Ahead

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Capsida has reported a patient death in a gene therapy trial for epilepsy, but the exact cause of death has not been disclosed. The patient had received the gene therapy cap-002. ## The FDA is looking to streamline the development of non-opioid painkillers, while Avidity has seen functional improvements in their DMD therapy. ## The White House is reportedly consi...

3 weeks ago

Pharma and BioTech Daily

Pharma and Biotech Daily: Top Headlines in the Industry

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk has cut 9,000 jobs worldwide and reduced its 2025 profit growth guidance. The new CEO is fulfilling a cost reallocation promise, leading to a decrease in operating profit growth projection from 10% to 16% down to 4% to 10%. The company's restructuring efforts are aimed at increasing efficiency and reducing costs. In other news, the ousted CDC director Sus...

3 weeks ago

1 minute

Pharma and BioTech Daily

Pharma and Biotech Daily: Novartis Acquires Tourmaline for $1.4 Billion and Biogen Prepares to Release New Lupus Data

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Novartis recently acquired Tourmaline for $1.4 billion, continuing its investment in cardiovascular treatments. The company has also made other partnerships in the cardiovascular space this year. Biogen is preparing to release new data on its lupus treatments, with analysts praising the company's pipeline. Novartis has been active in mergers and acquisitions, p...

4 weeks ago